Breaking News

ALPN

Alpine Immune Sciences

13
Jun

03/24/23 H.C. Wainwright: Alpine Immune Sciences price target raised to $11 from $8 at H.C. Wainwright

01/19/23 Morgan Stanley: Alpine Immune Sciences initiated with an Overweight at Morgan Stanley

11/21/22 SVB Securities: Alpine Immune Sciences initiated with an Outperform at SVB Securities

10/24/22 Oppenheimer: Alpine Immune price target lowered to $14 from $17 at Oppenheimer

Clear This Search Refresh Search

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Earnings	Alpine Immune Sciences reports Q1 EPS (28c), consensus (37c) » 16:21 05/11/23 05/11 16:21 05/11/23 16:21 ALPN Alpine Immune Sciences $7.80 / -0.05 (-0.64%) "So far this year,… "So far this year, we have achieved important milestones in advancing clinical studies for povetacicept, our potential best-in-class dual BAFF/APRIL inhibitor being developed for multiple autoantibody-related diseases. The first participant was dosed in the RUBY-3 study of povetacicept in autoimmune glomerulonephritis and we are pleased with the high level of investigator interest in the study. We've also opened the RUBY-4 study of povetacicept in autoimmune cytopenias and are preparing to initiate enrollment this quarter," said Mitchell H. Gold, MD, Executive Chairman and Chief Executive Officer of Alpine. "We remain on track to deliver preliminary data from both the RUBY-3 and RUBY-4 studies by the end of the year as we continue to pursue our mission of bringing meaningful new therapies to people living with autoimmune or inflammatory diseases." ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events ALPN Alpine Immune Sciences $7.80 / -0.05 (-0.64%) 03/22/23 Alpine Immune Sciences, Truveta enter strategic partnership ALPN Alpine Immune Sciences $7.80 / -0.05 (-0.64%) 03/24/23 H.C. Wainwright Alpine Immune Sciences price target raised to $11 from $8 at H.C. Wainwright 01/19/23 Morgan Stanley Alpine Immune Sciences initiated with an Overweight at Morgan Stanley 11/21/22 SVB Securities Alpine Immune Sciences initiated with an Outperform at SVB Securities 10/24/22 Oppenheimer Alpine Immune price target lowered to $14 from $17 at Oppenheimer ALPN Alpine Immune Sciences $7.80 / -0.05 (-0.64%) 03/23/23 Alpine Immune Sciences reports Q4 EPS (41c), consensus (27c) 11/14/22 Alpine Immune Sciences reports Q3 EPS (42c), consensus (10c) 21 Sep ALPN Alpine Immune Sciences $7.80 / -0.05 (-0.64%) 01/19/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/13/23 Alpine Immune Sciences Inc

Over a month ago
Syndicate	Alpine Immune Sciences files $400M mixed securities shelf 16:59 04/28/23 04/28 16:59 04/28/23 16:59 ALPN Alpine Immune Sciences $7.50 / +0.27 (+3.73%) ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events ALPN Alpine Immune Sciences $7.50 / +0.27 (+3.73%) 03/22/23 Alpine Immune Sciences, Truveta enter strategic partnership ALPN Alpine Immune Sciences $7.50 / +0.27 (+3.73%) 03/24/23 H.C. Wainwright Alpine Immune Sciences price target raised to $11 from $8 at H.C. Wainwright 01/19/23 Morgan Stanley Alpine Immune Sciences initiated with an Overweight at Morgan Stanley 11/21/22 SVB Securities Alpine Immune Sciences initiated with an Outperform at SVB Securities 10/24/22 Oppenheimer Alpine Immune price target lowered to $14 from $17 at Oppenheimer ALPN Alpine Immune Sciences $7.50 / +0.27 (+3.73%) 03/23/23 Alpine Immune Sciences reports Q4 EPS (41c), consensus (27c) 11/14/22 Alpine Immune Sciences reports Q3 EPS (42c), consensus (10c) 21 Sep ALPN Alpine Immune Sciences $7.50 / +0.27 (+3.73%) 01/19/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/13/23 Alpine Immune Sciences Inc
Recommendations	Alpine Immune Sciences price target raised to $11 from $8 at H.C. Wainwright » 06:11 03/24/23 03/24 06:11 03/24/23 06:11 ALPN Alpine Immune Sciences $8.12 / +0.19 (+2.40%) H.C. Wainwright analyst… H.C. Wainwright analyst Joseph Pantginis raised the firm's price target on Alpine Immune Sciences to $11 from $8 and keeps a Buy rating on the shares post the Q4 results. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly ALPN Alpine Immune Sciences $8.12 / +0.19 (+2.40%) 03/22/23 Alpine Immune Sciences, Truveta enter strategic partnership 10/24/22 Alpine Immune Sciences terminates enrollment of davoceticept clinical studies ALPN Alpine Immune Sciences $8.12 / +0.19 (+2.40%) 01/19/23 Morgan Stanley Alpine Immune Sciences initiated with an Overweight at Morgan Stanley 11/21/22 SVB Securities Alpine Immune Sciences initiated with an Outperform at SVB Securities 10/24/22 Oppenheimer Alpine Immune price target lowered to $14 from $17 at Oppenheimer 10/24/22 H.C. Wainwright Alpine Immune Sciences price target lowered to $8 from $21 at H.C. Wainwright ALPN Alpine Immune Sciences $8.12 / +0.19 (+2.40%) 03/23/23 Alpine Immune Sciences reports Q4 EPS (41c), consensus (27c) 11/14/22 Alpine Immune Sciences reports Q3 EPS (42c), consensus (10c) 21 Sep ALPN Alpine Immune Sciences $8.12 / +0.19 (+2.40%) 01/19/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Earnings	Alpine Immune Sciences reports Q4 EPS (41c), consensus (27c) » 16:12 03/23/23 03/23 16:12 03/23/23 16:12 ALPN Alpine Immune Sciences $8.12 / +0.19 (+2.40%) "With the recent… "With the recent initiation of the RUBY-3 study in autoimmune glomerulonephritis and the imminent initiation of the RUBY-4 study in autoimmune cytopenias, 2023 is on track to be a pivotal year for Alpine and povetacicept, a potential best-in-class dual BAFF/APRIL inhibitor which we are developing for multiple autoantibody-related diseases. We look forward to sharing updates on both studies anticipated by the end of the year," said Mitchell H. Gold, MD, Executive Chairman and Chief Executive Officer of Alpine. "Our strong balance sheet and povetacicept's promising preclinical and phase 1 healthy volunteer data, in addition to a convenient once every four-week subcutaneous dosing regimen, enables us to advance a robust development plan which has the potential to bring a meaningful new therapeutic option for patients living with multiple different autoimmune or inflammatory diseases." ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events ALPN Alpine Immune Sciences $8.12 / +0.19 (+2.40%) 03/22/23 Alpine Immune Sciences, Truveta enter strategic partnership 10/24/22 Alpine Immune Sciences terminates enrollment of davoceticept clinical studies ALPN Alpine Immune Sciences $8.12 / +0.19 (+2.40%) 01/19/23 Morgan Stanley Alpine Immune Sciences initiated with an Overweight at Morgan Stanley 11/21/22 SVB Securities Alpine Immune Sciences initiated with an Outperform at SVB Securities 10/24/22 Oppenheimer Alpine Immune price target lowered to $14 from $17 at Oppenheimer 10/24/22 H.C. Wainwright Alpine Immune Sciences price target lowered to $8 from $21 at H.C. Wainwright ALPN Alpine Immune Sciences $8.12 / +0.19 (+2.40%) 11/14/22 Alpine Immune Sciences reports Q3 EPS (42c), consensus (10c) 21 Sep ALPN Alpine Immune Sciences $8.12 / +0.19 (+2.40%) 01/19/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/23/23 Alpine Immune Sciences - ALPN
Hot Stocks	Alpine Immune Sciences, Truveta enter strategic partnership » 08:46 03/22/23 03/22 08:46 03/22/23 08:46 ALPN Alpine Immune Sciences $8.00 / -0.175 (-2.14%) Truveta and Alpine Immune… Truveta and Alpine Immune Sciences announced a strategic partnership to help accelerate clinical trial recruitment for povetacicept, Alpine's dual B cell cytokine antagonist being developed for multiple B cell-mediated autoimmune and inflammatory diseases. With this partnership, Alpine and Truveta will work to rapidly identify and recruit participants for Alpine's RUBY clinical trial program for povetacicept, including the RUBY-3 study in autoimmune glomerulonephritis and RUBY-4 study in autoimmune cytopenias. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events ALPN Alpine Immune Sciences $8.00 / -0.175 (-2.14%) 10/24/22 Alpine Immune Sciences terminates enrollment of davoceticept clinical studies ALPN Alpine Immune Sciences $8.00 / -0.175 (-2.14%) 01/19/23 Morgan Stanley Alpine Immune Sciences initiated with an Overweight at Morgan Stanley 11/21/22 SVB Securities Alpine Immune Sciences initiated with an Outperform at SVB Securities 10/24/22 Oppenheimer Alpine Immune price target lowered to $14 from $17 at Oppenheimer 10/24/22 H.C. Wainwright Alpine Immune Sciences price target lowered to $8 from $21 at H.C. Wainwright ALPN Alpine Immune Sciences $8.00 / -0.175 (-2.14%) 11/14/22 Alpine Immune Sciences reports Q3 EPS (42c), consensus (10c) 21 Sep ALPN Alpine Immune Sciences $8.00 / -0.175 (-2.14%) 01/19/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/23/23 Alpine Immune Sciences - ALPN

Over a quarter ago
On The Fly	Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 10:14 01/19/23 01/19 10:14 01/19/23 10:14 PTEN Patterson-UTI $16.10 / -0.01 (-0.06%) , IBM IBM $141.12 / +0.73 (+0.52%) , OLED Universal Display $127.44 / -0.06 (-0.05%) , PM Philip Morris $101.60 / +2.36 (+2.38%) , CHGG Chegg $20.49 / +0.12 (+0.59%) , CVAC CureVac $9.87 / +0.385 (+4.06%) , RBLX Roblox $33.32 / -2.44 (-6.82%) , SCHW Charles Schwab $77.18 / -4.205 (-5.17%) , CTSH Cognizant $60.94 / -0.04 (-0.07%) , DXC DXC Technology $28.35 / -0.615 (-2.12%) , TEVA Teva $10.36 / -0.485 (-4.47%) , TEL TE Connectivity $121.17 / -2.06 (-1.67%) , SHYF Shyft Group $30.25 / +0.82 (+2.79%) , GEHC GE HealthCare $62.75 / +0.74 (+1.19%) , HAL Halliburton $40.42 / -0.13 (-0.32%) , WHD Cactus $51.81 / -0.96 (-1.82%) , NE Noble Corp. $40.02 / +0.295 (+0.74%) , VAL Valaris $73.00 / +0.94 (+1.30%) , FTI TechnipFMC $12.55 / +0.13 (+1.05%) , RIG Transocean $5.87 / +0.15 (+2.62%) , OII Oceaneering $18.39 / +0.045 (+0.25%) , NOV NOV Inc. $22.58 / -0.225 (-0.99%) , BKR Baker Hughes $30.54 / -0.13 (-0.42%) , SLB SLB $56.74 / -0.38 (-0.67%) , HP Helmerich & Payne $47.17 / -0.355 (-0.75%) , PUMP ProPetro Holding $9.42 / -0.055 (-0.58%) , ALPN Alpine Immune Sciences $8.09 / +0.12 (+1.51%) , KPTI Karyopharm $3.26 / +0.19 (+6.20%) Institutional investors… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options WHD VAL TEVA TEL SLB SHYF SCHW RIG RBLX PUMP PTEN PM OLED OII NE KPTI IBM HP HAL GEHC FTI DXC CVAC CTSH CHGG BKR ALPN WHD Cactus $51.81 / -0.96 (-1.82%) 01/10/23 Cactus falls 4% afterhours to $54.65 after offering $125M in common stock 01/03/23 Cactus to acquire FlexSteel for total upfront consideration of $621M VAL Valaris $73.00 / +0.94 (+1.30%) 12/15/22 Valaris announces contract awards with backlog of roughly $275M 11/21/22 Valaris announces contract award for drillship VALARIS DS-12 11/14/22 Elliott made Triple Flag Precious Metals top holding during Q3 10/03/22 Valaris announces contract backlog of $95M TEVA Teva $10.36 / -0.485 (-4.47%) 01/19/23 Teva announces targets to reduce GHG emissions approved by SBTi 01/09/23 Teva announces nationwide opioids settlement after receiving state support 01/06/23 Alvotech, Teva announce FDA acceptance of AVT04 BLA for review 12/22/22 Alvotech announces FDA grants BsUFA goal date for AVT02 BLA TEL TE Connectivity $121.17 / -2.06 (-1.67%) 12/09/22 TE Connectivity increases quarterly dividend to 59c per share 10/20/22 OrthoPediatrics announces appointment of McDonald to board of directors SLB SLB $56.74 / -0.38 (-0.67%) 11/22/22 SLB announces award to its OneSubsea business 11/16/22 SLB teams with Oman to build national strategy to develop geothermal resources 11/15/22 SLB exec Mogharbel Khaled Al sells 57,467 common shares 11/08/22 SLB CAO Guild sells 20,053 common shares SHYF Shyft Group $30.25 / +0.82 (+2.79%) 01/18/23 Red Diamond Aftermarket Solutions to exhibit at Florida RV SuperShow 01/04/23 Shyft Group completes acquisition of XL Fleet 12/14/22 Shyft Group appoints Dunn as President, Fleet Vehicles, Services 10/04/22 Shyft Group announces Blue Arc ride and drive event SCHW Charles Schwab $77.18 / -4.205 (-5.17%) 01/19/23 Toronto-Dominion comments on expected impact of Charles Schwab's Q4 earnings 12/13/22 E*TRADE from Morgan Stanley eliminates commissions for all online mutual funds RIG Transocean $5.87 / +0.15 (+2.62%) 01/17/23 Transocean announces proposed private offering of $1.175B 01/09/23 Transocean announces proposed private offering of $500M 01/04/23 Transocean announces contract awards and extensions totaling $488M 12/07/22 Transocean announces $1.04B contract award for ultra-deepwater drillships RBLX Roblox $33.32 / -2.44 (-6.82%) 01/19/23 Roblox falls 7% to $33.33 in pre-market after Morgan Stanley downgrade 01/18/23 Roblox CEO says community grew 23% in 2022 to over 56M daily users 01/17/23 Roblox rises 12.6% 01/17/23 Roblox rises 11.2% PUMP ProPetro Holding $9.42 / -0.055 (-0.58%) 12/19/22 ProPetro Holding appoints John Mitchell as General Counsel 12/06/22 ProPetro Holding executes contract with independent Permian operator 11/01/22 ProPetro acquires Silvertip in cash and stock deal 11/01/22 ProPetro sees FY22 cash CapEx roughly $325M PTEN Patterson-UTI $16.10 / -0.01 (-0.06%) 01/04/23 Patterson-UTI sees Q4 net income exceeding $100M, adjusted EBITDA over $230M 12/05/22 Patterson-UTI reports an average of 131 drilling rigs operating in November 11/03/22 Patterson-UTI reports an average of 131 drilling rigs operating in October 10/05/22 Patterson-UTI reports an average of 130 drilling rigs operating in September PM Philip Morris $101.60 / +2.36 (+2.38%) 01/08/23 Fly Intel: Top five weekend stock stories 12/11/22 Fly Intel: Top five weekend stock stories 11/28/22 Philip Morris Holland Holdings becomes owner of 93.11% of Swedish Match shares 11/25/22 Philip Morris announces new regional structure, management changes OLED Universal Display $127.44 / -0.06 (-0.05%) 01/17/23 Universal Display, Seiko Epson announce OLED evaluation agreement 12/05/22 Universal Display signs OLED supply, license agreements with Samsung Display 10/26/22 OTI Lumionics raises $55M in Series B funding 08/04/22 Universal Display CFO Rosenblatt to retire OII Oceaneering $18.39 / +0.045 (+0.25%) 10/27/22 Oceaneering rises 19.0% 10/26/22 Oceaneering sees FY23 consolidated EBITDA $260M-$310M 10/13/22 Oceaneering wins $300M of subsea robotics contracts 08/24/22 Oceaneering names Benjamin Laura CIO NE Noble Corp. $40.02 / +0.295 (+0.74%) 11/03/22 Noble Corp. sees Q4 adjusted EBITDA $155M-$175M 10/05/22 Noble Corp. completes divestment of five jackups 08/15/22 Elliott buys Pinterest, exits Twitter in Q2 KPTI Karyopharm $3.26 / +0.19 (+6.20%) 12/12/22 Karyopharm announces updated results from Phase 1 selinexor data 11/03/22 Karyopharm to present new selinexor data in myelofibrosis and myeloma 11/01/22 Karyopharm, Menarini Group: EC grants orphan designation for selinexor 10/31/22 Karyopharm and Menarini announce EC granted orphan designation for selinexor IBM IBM $141.12 / +0.73 (+0.52%) 01/10/23 Intel unveils 4th Gen Xeon Scalable processors, Xeon CPU Max Series 01/04/23 IBM announces IBM Partner Plus program 12/13/22 IBM, Rapidus announce joint development pact ro advance logic scaling in Japan 12/09/22 IBM Canada to open Client Innovation Centre in Fredericton HP Helmerich & Payne $47.17 / -0.355 (-0.75%) 11/07/22 Trimble, HP to collaborate on robotic technology for autonomous construction 10/31/22 Tenable announces Michelle VonderHaar as chief legal officer, general counsel 10/18/22 Helmerich & Payne announces FY23 capex budget of $425M-$475M 10/18/22 Helmerich & Payne announces $100M supplemental shareholder return plan HAL Halliburton $40.42 / -0.13 (-0.32%) 10/25/22 Halliburton CEO says 'strong margin performance in both divisions' in Q3 09/19/22 Halliburton signs MoU with SDAIA for AI predictions 09/08/22 Halliburton completes sale of Russian operations 07/19/22 Halliburton CEO: Automation is changing the drilling landscape GEHC GE HealthCare $62.75 / +0.74 (+1.19%) 01/09/23 GE HealthCare announces acquisition of CT firm Imactis, terms undisclosed 01/09/23 GE HealthCare to acquire IMACTIS, terms not disclosed 01/05/23 GE HealthCare names Taha Kass-Hout CTO 01/04/23 GE HealthCare completes spin-off from GE, starts trading on Nasdaq FTI TechnipFMC $12.55 / +0.13 (+1.05%) 01/10/23 TechnipFMC awarded 'significant' contract by Wintershall Dea 09/22/22 TechnipFMC awarded 'significant' subsea contract for Shell development 09/14/22 TechnipFMC awarded subsea contract by TotalEnergies 08/01/22 TechnipFMC awarded contract for energy project in Guyana DXC DXC Technology $28.35 / -0.615 (-2.12%) 10/27/22 DXC Technology announces expanded partnership with Dynatrace 10/04/22 DXC Technology up 6%, trims gain after saying no formal offer made by suitor 10/04/22 DXC Technology Co trading resumes 10/04/22 DXC Technology confirms acquisition approach, says engaged in talks CVAC CureVac $9.87 / +0.385 (+4.06%) 01/09/23 CureVac appoints Alexander Zehnder as CEO 01/06/23 CureVac announces data on joint COVID-19, Flu mRNA vaccine programs 11/16/22 CureVac, GSK teamed on 4 Phase 1 studies in COVID-19 and flu vaccines 11/16/22 CureVac reports cash equivalents position of EUR 540.9M at September-end CTSH Cognizant $60.94 / -0.04 (-0.07%) 01/12/23 Cognizant appoints Ravi Kumar S as CEO 01/12/23 Cognizant appoints Ravi Kumar S as CEO 12/15/22 Cognizant, Syniti announce strategic alliance agreement 12/07/22 Cognizant to acquire Utegration, terms not disclosed CHGG Chegg $20.49 / +0.12 (+0.59%) 01/19/23 Chegg rises 4.4% 01/18/23 Chegg falls -14.9% 01/18/23 Chegg falls -10.5% 01/18/23 Chegg falls -6.4% BKR Baker Hughes $30.54 / -0.13 (-0.42%) 01/17/23 Archer announces term sheet to potentially acquire Baker Hughes unit in U.K. 01/13/23 Baker Hughes reports U.S. rig count up 3 to 775 rigs 01/09/23 Baker Hughes appoints Ganesh Ramaswamy as EVP, IET business 01/06/23 Baker Hughes reports U.S. rig count down 7 to 772 rigs ALPN Alpine Immune Sciences $8.09 / +0.12 (+1.51%) 10/24/22 Alpine Immune Sciences terminates enrollment of davoceticept clinical studies PTEN IBM OLED PM CHGG CVAC RBLX SCHW CTSH DXC TEVA TEL SHYF GEHC HAL WHD NE VAL FTI RIG OII NOV BKR SLB HP PUMP ALPN KPTI PTEN Patterson-UTI $16.10 / -0.01 (-0.06%) 01/19/23 Benchmark Patterson-UTI initiated with a Hold at Benchmark 01/17/23 Citi Patterson-UTI downgraded to Neutral from Buy at Citi 12/09/22 Raymond James Patterson-UTI initiated with a Strong Buy at Raymond James 10/07/22 Piper Sandler Patterson-UTI assumed with an Overweight at Piper Sandler IBM IBM $141.12 / +0.73 (+0.52%) 01/19/23 MoffettNathanson IBM upgraded to Market Perform from Underperform at MoffettNathanson 01/18/23 Morgan Stanley IBM downgraded to Equal Weight at Morgan Stanley amid shift away from defense 01/18/23 Morgan Stanley IBM downgraded to Equal Weight from Overweight at Morgan Stanley 01/17/23 Evercore ISI IBM price target raised to $150 from $135 at Evercore ISI OLED Universal Display $127.44 / -0.06 (-0.05%) 01/19/23 Susquehanna Universal Display upgraded to Neutral from Negative at Susquehanna 11/21/22 Citi Universal Display price target lowered to $135 from $150 at Citi 11/04/22 Oppenheimer Universal Display price target lowered to $135 from $150 at Oppenheimer 11/04/22 TD Cowen Universal Display price target lowered to $130 from $145 at Cowen PM Philip Morris $101.60 / +2.36 (+2.38%) 01/19/23 Jefferies Philip Morris upgraded at Jefferies as tobacco sentiment may 'finally' improve 01/19/23 Jefferies Philip Morris upgraded to Buy from Hold at Jefferies 12/13/22 Citi Philip Morris resumed with a Neutral at Citi 11/15/22 Argus Philip Morris upgraded to Buy from Hold at Argus CHGG Chegg $20.49 / +0.12 (+0.59%) 01/19/23 KeyBanc Chegg upgraded to Overweight on margin potential at KeyBanc 01/19/23 KeyBanc Chegg upgraded to Overweight from Sector Weight at KeyBanc 01/18/23 BMO Capital Chegg traffic declining as ChatGPT may pose subs headwinds, says BMO Capital 01/18/23 Needham Needham downgrades Chegg to Hold as long-term initiatives limit growth upside CVAC CureVac $9.87 / +0.385 (+4.06%) 01/19/23 UBS UBS upgrades CureVac after 'major milestone and clearing event' 01/19/23 UBS CureVac upgraded to Buy from Neutral at UBS 01/09/23 Jefferies CureVac upgraded to Buy at Jefferies after mRNA platform validation 01/09/23 Jefferies CureVac upgraded to Buy from Hold at Jefferies RBLX Roblox $33.32 / -2.44 (-6.82%) 01/19/23 Morgan Stanley Roblox downgraded to Underweight from Equal Weight at Morgan Stanley 01/19/23 Morgan Stanley Roblox downgraded to Underweight from Equal Weight at Morgan Stanley 01/18/23 Needham Roblox price target raised to $42 from $39 at Needham 01/18/23 BTIG Roblox December outperformance due to core monetization, gift cards, says BTIG SCHW Charles Schwab $77.18 / -4.205 (-5.17%) 01/19/23 BofA Charles Schwab double downgraded to Underperform at BofA 01/19/23 BofA Charles Schwab downgraded to Underperform from Buy at BofA 01/17/23 William Blair Charles Schwab initiated with an Outperform at William Blair 01/04/23 Goldman Sachs Charles Schwab upgraded to Buy from Neutral at Goldman Sachs CTSH Cognizant $60.94 / -0.04 (-0.07%) 01/19/23 MoffettNathanson Cognizant downgraded to Underperform from Market Perform at MoffettNathanson 01/15/23 UBS Cognizant price target raised to $68 from $62 at UBS 01/13/23 BMO Capital Cognizant price target raised to $71 from $65 at BMO Capital 01/09/23 BofA Cognizant downgraded to Underperform from Neutral at BofA DXC DXC Technology $28.35 / -0.615 (-2.12%) 01/19/23 MoffettNathanson DXC Technology downgraded to Underperform at MoffettNathanson 12/15/22 JPMorgan DXC Technology upgraded to Neutral from Underweight at JPMorgan 10/14/22 JPMorgan DXC Technology price target lowered to $31 from $33 at JPMorgan 10/05/22 Citi Citi says $38 target on DXC does not include buyout premium TEVA Teva $10.36 / -0.485 (-4.47%) 01/19/23 Jefferies Teva downgraded to Hold from Buy at Jefferies 01/06/23 Northland Alvotech named a top pick for 2023 at Northland 11/23/22 Piper Sandler Teva price target lowered to $7 from $8 at Piper Sandler 11/14/22 JPMorgan Teva downgraded to Underweight from Neutral at JPMorgan TEL TE Connectivity $121.17 / -2.06 (-1.67%) 01/19/23 Evercore ISI TE Connectivity downgraded to In Line at Evercore ISI on auto market headwinds 01/19/23 Evercore ISI TE Connectivity downgraded to In Line from Outperform at Evercore ISI 12/20/22 JPMorgan TE Connectivity price target lowered to $130 from $135 at JPMorgan 12/12/22 Credit Suisse TE Connectivity initiated with a Neutral at Credit Suisse SHYF Shyft Group $30.25 / +0.82 (+2.79%) 01/19/23 BTIG Shyft Group initiated with a Buy at BTIG 07/13/22 DA Davidson Shyft Group upgraded to Buy at DA Davidson on improving commercial van sales 07/13/22 DA Davidson Shyft Group upgraded to Buy from Neutral at DA Davidson 04/06/22 DA Davidson DA Davidson cuts Shyft Group to Neutral, citing caution on near-term earnings GEHC GE HealthCare $62.75 / +0.74 (+1.19%) 01/19/23 Redburn GE HealthCare initiated with a Buy at Redburn 01/09/23 BofA General Electric price target lowered to $85 from $105 at BofA 01/04/23 Edward Jones GE HealthCare initiated with a Hold at Edward Jones 12/06/22 Oppenheimer General Electric upgraded to Outperform from Perform at Oppenheimer HAL Halliburton $40.42 / -0.13 (-0.32%) 01/19/23 Benchmark Halliburton initiated with a Buy at Benchmark 01/12/23 Wolfe Research Halliburton upgraded to Outperform from Underperform at Wolfe Research 12/09/22 Raymond James Halliburton initiated with a Strong Buy at Raymond James 11/29/22 Citi Halliburton should take equity stake in Chart Industries, says Citi WHD Cactus $51.81 / -0.96 (-1.82%) 01/19/23 Benchmark Cactus initiated with a Buy at Benchmark 11/13/22 Citi Cactus price target raised to $58 from $47 at Citi 11/08/22 BofA Cactus price target raised to $59 from $45 at BofA 10/07/22 Piper Sandler Cactus assumed with a Neutral at Piper Sandler NE Noble Corp. $40.02 / +0.295 (+0.74%) 01/19/23 Benchmark Noble Corp. initiated with a Buy at Benchmark 07/06/22 DNB Markets Noble Corp. price target raised to $49 from $43 at DNB Markets 06/01/22 BTIG Noble Corp. upgraded to Buy from Neutral at BTIG 02/08/22 Evercore ISI Noble Corp. resumed with an Outperform at Evercore ISI VAL Valaris $73.00 / +0.94 (+1.30%) 01/19/23 Benchmark Valaris initiated with a Buy at Benchmark 01/03/23 BTIG Helix Energy named Top Pick for first half of 2023 at BTIG 06/01/22 BTIG Valaris price target raised to $80 from $60 at BTIG FTI TechnipFMC $12.55 / +0.13 (+1.05%) 01/19/23 Benchmark TechnipFMC initiated with a Buy at Benchmark 01/03/23 BTIG TechnipFMC named Top Pick for first half of 2023 at BTIG 11/18/22 Piper Sandler TechnipFMC price target raised to $17 from $13 at Piper Sandler 10/25/22 HSBC TechnipFMC upgraded to Buy from Hold at HSBC RIG Transocean $5.87 / +0.15 (+2.62%) 01/19/23 Benchmark Transocean initiated with a Buy at Benchmark 11/18/22 Piper Sandler Transocean price target raised to $5 from $4 at Piper Sandler 10/17/22 Susquehanna Transocean price target lowered to $3.30 from $4.20 at Susquehanna 10/07/22 Piper Sandler Transocean assumed with a Neutral at Piper Sandler OII Oceaneering $18.39 / +0.045 (+0.25%) 01/19/23 Benchmark Oceaneering initiated with a Buy at Benchmark 10/19/22 Citi Oceaneering price target lowered to $16 from $20 at Citi 10/07/22 Piper Sandler Oceaneering assumed with a Neutral at Piper Sandler 10/06/22 Barclays Barclays downgrades Oceaneering on lack of 'earnings torque' NOV NOV Inc. $22.58 / -0.225 (-0.99%) 01/19/23 Benchmark NOV Inc. initiated with a Buy at Benchmark 01/04/23 Morgan Stanley NOV Inc. upgraded to Overweight from Equal Weight at Morgan Stanley 12/09/22 Raymond James NOV Inc. initiated with an Outperform at Raymond James 11/07/22 Wells Fargo Wells Fargo upgrades NOV Inc. to Equal Weight, raises price target to $25 BKR Baker Hughes $30.54 / -0.13 (-0.42%) 01/19/23 Benchmark Baker Hughes initiated with a Buy at Benchmark 10/26/22 Wells Fargo Wells Fargo downgrades 'show me' stock Baker Hughes to neutral 10/26/22 Wells Fargo Baker Hughes downgraded to Equal Weight from Overweight at Wells Fargo SLB SLB $56.74 / -0.38 (-0.67%) 01/19/23 Benchmark SLB initiated with a Buy at Benchmark 01/12/23 Wolfe Research SLB downgraded to Peer Perform from Outperform at Wolfe Research 12/09/22 Raymond James SLB initiated with an Outperform at Raymond James 11/18/22 Piper Sandler SLB price target raised to $64 from $60 at Piper Sandler HP Helmerich & Payne $47.17 / -0.355 (-0.75%) 01/19/23 Benchmark Helmerich & Payne initiated with a Hold at Benchmark 01/09/23 BofA Helmerich & Payne upgraded to Buy from Neutral at BofA 11/18/22 RBC Capital Helmerich & Payne price target raised to $68 from $63 at RBC Capital 11/18/22 Susquehanna Helmerich & Payne price target raised to $65 from $62 at Susquehanna PUMP ProPetro Holding $9.42 / -0.055 (-0.58%) 01/19/23 Benchmark ProPetro Holding initiated with a Hold at Benchmark 01/17/23 Citi ProPetro Holding downgraded to Neutral from Buy at Citi 01/10/23 Barclays ProPetro Holding upgraded to Overweight from Equal Weight at Barclays 10/07/22 Piper Sandler ProPetro Holding assumed with an Overweight at Piper Sandler ALPN Alpine Immune Sciences $8.09 / +0.12 (+1.51%) 01/19/23 Morgan Stanley Alpine Immune Sciences initiated with an Overweight at Morgan Stanley 11/21/22 SVB Securities Alpine Immune Sciences initiated with an Outperform at SVB Securities 10/24/22 Oppenheimer Alpine Immune price target lowered to $14 from $17 at Oppenheimer 10/24/22 H.C. Wainwright Alpine Immune Sciences price target lowered to $8 from $21 at H.C. Wainwright KPTI Karyopharm $3.26 / +0.19 (+6.20%) 01/19/23 Piper Sandler Karyopharm initiated with an Overweight at Piper Sandler 01/10/23 H.C. Wainwright Karyopharm price target lowered to $16 from $18 at H.C. Wainwright 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks 11/04/22 RBC Capital Karyopharm upgraded to Outperform from Sector Perform at RBC Capital WHD VAL TEVA TEL SLB SHYF SCHW RIG RBLX PUMP PTEN PM OLED OII NOV NE KPTI IBM HP HAL GEHC FTI DXC CVAC CTSH CHGG BKR ALPN WHD Cactus $51.81 / -0.96 (-1.82%) 11/07/22 Cactus reports Q3 adjusted EPS 52c, consensus 48c 08/04/22 Cactus reports Q2 adjusted EPS 44c, consensus 35c VAL Valaris $73.00 / +0.94 (+1.30%) 11/01/22 Valaris reports Q3 EPS 98c, consensus 36c 08/02/22 Valaris reports Q2 EPS $1.48, consensus (9c) TEVA Teva $10.36 / -0.485 (-4.47%) 11/03/22 Teva backs FY22 EPS view $2.40-$2.60, consensus $2.50 11/03/22 Teva reports Q3 EPS 59c, consensus 62c 07/26/22 Teva backs FY22 EPS view of $2.40-$2.60, consensus $2.46 07/26/22 Teva reports Q2 EPS 68c, consensus 57c TEL TE Connectivity $121.17 / -2.06 (-1.67%) 11/02/22 TE Connectivity sees Q1 adjusted EPS $1.50, consensus $1.73 11/02/22 TE Connectivity reports Q4 adjusted EPS $1.88, consensus $1.88 07/27/22 TE Connectivity sees Q4 EPS $1.85, consensus $1.81 07/27/22 TE Connectivity reports Q3 adjusted EPS $1.86, consensus $1.75 SLB SLB $56.74 / -0.38 (-0.67%) 10/21/22 Schlumberger reports Q3 adjusted EPS 63c, consensus 56c 07/22/22 Schlumberger raises FY22 revenue view to 'at least' $27B, consensus $25.71B 07/22/22 Schlumberger reports Q2 adjusted EPS 50c, consensus 39c SHYF Shyft Group $30.25 / +0.82 (+2.79%) 10/27/22 Shyft Group narrows FY22 adjusted EPS view $1.02-$1.24 from 85c-$1.41 10/27/22 Shyft Group reports Q3 adjusted EPS 53c, consensus 44c 07/28/22 Shyft Group raises FY22 adjusted EPS 85c-$1.41 from 75c-$1.41, consensus $1.10 07/28/22 Shyft Group reports Q2 adjusted EPS 21c, consensus 18c SCHW Charles Schwab $77.18 / -4.205 (-5.17%) 01/18/23 Charles Schwab reports Q4 adjusted EPS $1.07, consensus $1.09 01/17/23 Notable companies reporting before tomorrow's open 10/27/22 Charles Schwab backs 11%-13% year-over-year revenue growth outlook RIG Transocean $5.87 / +0.15 (+2.62%) 11/03/22 Transocean sees 2023 adjusted contract drilling revenue of $2.9B-$3B 11/03/22 Transocean sees Q4 adjusted contract drilling revenue of about $600M 11/02/22 Transocean reports Q3 EPS (4c), consensus (18c) 08/01/22 Transocean reports Q2 EPS (10c) vs. (17c) last year RBLX Roblox $33.32 / -2.44 (-6.82%) 11/09/22 Roblox reports Q3 EPS (50c), consensus (33c) 11/08/22 Notable companies reporting before tomorrow's open 08/09/22 Roblox reports Q2 EPS (30c), consensus (23c) PUMP ProPetro Holding $9.42 / -0.055 (-0.58%) 11/01/22 ProPetro Holding reports Q3 EPS 10c, consensus 31c 08/02/22 ProPetro Holding sees FY22 adjusted EBITDA at or above $300M 08/02/22 ProPetro Holding reports Q2 EPS (32c) with items, consensus 25c PTEN Patterson-UTI $16.10 / -0.01 (-0.06%) 10/26/22 Patterson-UTI reports Q3 EPS 28c, consensus 18c 07/27/22 Patterson-UTI reports Q2 EPS 10c, consensus (4c) PM Philip Morris $101.60 / +2.36 (+2.38%) 01/12/23 Philip Morris expects 2022 results to be broadly in line with prior guidance 10/20/22 Philip Morris affirms FY22 view for pro forma adjusted EPS ex-FX $6.09-$6.20 10/20/22 Philip Morris reports Q3 EPS $1.53, consensus $1.36 10/19/22 Notable companies reporting before tomorrow's open OLED Universal Display $127.44 / -0.06 (-0.05%) 11/03/22 Universal Display reports Q3 EPS $1.12, consensus 98c 08/04/22 Universal Display cuts FY22 revenue view to $600M, plus or minus $10M 08/04/22 Universal Display reports Q2 EPS 87c vs 85c last year OII Oceaneering $18.39 / +0.045 (+0.25%) 10/26/22 Oceaneering reports Q3 adjusted EPS 23c, consensus 11c 07/27/22 Oceaneering sees FY22 EBITDA margin averaging in high 20% range 07/27/22 Oceaneering reports Q2 adjusted EPS 7c, consensus 12c NOV NOV Inc. $22.58 / -0.225 (-0.99%) 10/27/22 NOV Inc. reports Q3 EPS 8c, consensus 15c 07/27/22 NOV Inc. reports Q2 EPS 18c, consensus 4c NE Noble Corp. $40.02 / +0.295 (+0.74%) 11/03/22 Noble Corp. reports Q3 adjusted EPS 50c, consensus 39c 08/08/22 Noble Corp. reports Q2 adjusted EPS 40c, consensus 46c KPTI Karyopharm $3.26 / +0.19 (+6.20%) 01/09/23 Karyopharm sees FY22 revenue $157.7M, consensus $161.68M 01/09/23 Karyopharm sees Q4 revenue $34.2M, consensus $38.13M 11/03/22 Karyopharm sees FY22 revenue $155M-$165M, consensus $157.23M 11/03/22 Karyopharm reports Q3 EPS (45) with items, consensus (57c) IBM IBM $141.12 / +0.73 (+0.52%) 10/19/22 IBM reports Q3 Software revenue $5.8B, up 14.2% in constant currency 10/19/22 IBM sees FY22 constant currency revenue growth above mid-single digit model 10/19/22 IBM reports Q3 adjusted EPS $1.81, consensus $1.77 10/19/22 Notable companies reporting after market close HP Helmerich & Payne $47.17 / -0.355 (-0.75%) 11/16/22 Helmerich & Payne reports Q4 adjusted EPS 45c, consensus 45c 07/27/22 Helmerich & Payne reports Q3 adjusted EPS 5c, consensus 5c HAL Halliburton $40.42 / -0.13 (-0.32%) 10/25/22 Halliburton reports Q3 EPS 60c, consensus 56c GEHC GE HealthCare $62.75 / +0.74 (+1.19%) 01/10/23 GE HealthCare sees FY23 organic revenue growth 5%-7% 01/10/23 GE HealthCare sees FY22 revenue about $18.3B 01/10/23 GE HealthCare sees Q4 revenue about $4.9B FTI TechnipFMC $12.55 / +0.13 (+1.05%) 10/26/22 TechnipFMC reports Q3 adjusted EPS 3c vs (6c) last year 07/27/22 TechnipFMC reports Q2 adjusted EPS 2c vs. (6c) last year DXC DXC Technology $28.35 / -0.615 (-2.12%) 11/03/22 DXC Technology backs FY23 adjusted EPS view $3.45-$3.75, consensus $3.52 11/03/22 DXC Technology sees Q3 adjusted EPS 80c-85c, consensus 97c 11/03/22 DXC Technology reports Q2 adjusted EPS 75c, consensus 73c 11/03/22 Notable companies reporting after market close CVAC CureVac $9.87 / +0.385 (+4.06%) 08/18/22 CureVac reports Q2 revenue EUR 20.1M vs. EUR 22.4M last year CTSH Cognizant $60.94 / -0.04 (-0.07%) 01/12/23 Cognizant now sees Q4 revenue $4.8B vs. prior $4.72B-$4.77B view 01/12/23 Cognizant now sees FY22 revenue $19.4B vs. prior view of $19.3B 01/12/23 Cognizant cuts FY22 adjusted EPS view to $4.38-$4.40 from $4.43-$4.46 11/02/22 Cognizant cuts FY22 adjusted EPS view to $4.43-$4.46 from $4.51-$4.57 CHGG Chegg $20.49 / +0.12 (+0.59%) 11/01/22 Chegg sees FY22 revenue $762M-$765M, consensus $760.7M 11/01/22 Chegg sees Q4 revenue $200M-$203M, consensus $204.8M 11/01/22 Chegg reports Q3 EPS $1.23, consensus 14c 08/04/22 Chegg sees FY22 revenue $745M-$770M, consensus $761.9M BKR Baker Hughes $30.54 / -0.13 (-0.42%) 10/19/22 Baker Hughes reports Q3 adjusted EPS 26c, consensus 24c 08/15/22 Team to sell Quest Integrity business to Baker Hughes for $280M 07/20/22 Baker Hughes reports Q2 EPS 11c, consensus 22c ALPN Alpine Immune Sciences $8.09 / +0.12 (+1.51%) 11/14/22 Alpine Immune Sciences reports Q3 EPS (42c), consensus (10c) 08/11/22 Alpine Immune Sciences reports Q2 EPS (60c), consensus (39c) 11 Jan 21 Sep 02 Aug TEVA SLB SCHW RBLX PM IBM DXC BKR TEVA Teva $10.36 / -0.485 (-4.47%) 11/03/22 Teva won't renew contract of CEO Kare Schultz, WSJ reports 10/07/22 Teva tells Bloomberg it sees Adderall supply issues for next 2-3 months 08/17/22 Generic drugmakers paid to settle first Zantac case before trial, Bloomberg says 08/02/22 Teva facing supply disruptions for ADHD drug Adderall, Bloomberg reports SLB SLB $56.74 / -0.38 (-0.67%) 10/14/22 Schlumberger faces backlash in Russia over draft cooperation, Reuters says 10/13/22 Schlumberger exploring $800M valves business sale, Bloomberg says 10/13/22 Schlumberger exploring sale of U.S. valves business, Bloomberg reports SCHW Charles Schwab $77.18 / -4.205 (-5.17%) 01/07/23 Charles Schwab stock ready to put 2022 behind it, time to buy, Barron's says 12/10/22 Microsoft, Arista among stocks that can survive a triple whammy, Barron's says 09/22/22 SEC to allow payment for order flow deals, Bloomberg reports 09/14/22 FTX raising capital while considering acquisitions, CoinDesk says RBLX Roblox $33.32 / -2.44 (-6.82%) 01/18/23 Video game sales fell 13% y/y in Europe in December, GI.biz says 12/28/22 Kids scamming kids on Roblox, IGN reports 11/30/22 Roblox nabs Apple executive for key engineering role, Axios reports 10/06/22 Roblox sued by watchdog group over girl's exploitation, Bloomberg reports PM Philip Morris $101.60 / +2.36 (+2.38%) 01/07/23 Philip Morris' stock about to get 'smoking hot,' Barron's says 12/12/22 Supreme Court declines to halt California flavored tobacco ban, Bloomberg says 11/06/22 Philip Morris wins Elliott's backing for Swedish Match deal, FT reports 10/24/22 Philip Morris to get EU approval for Swedish Match deal, Reuters reports IBM IBM $141.12 / +0.73 (+0.52%) 01/09/23 IBM to focus on open innovation, not patent leadership, Gil says in Fortune 11/11/22 IBM partners with new semiconductor company, FT reports 11/09/22 IBM engaged in talks with White House over quantum controls, Bloomberg says 09/17/22 IBM, CVS among cheap stocks not deserving to be in bargain bin, Barron's says DXC DXC Technology $28.35 / -0.615 (-2.12%) 10/04/22 Baring Private Equity Asia makes takeover approach to DXC, Bloomberg says 09/29/22 DXC takeover price near $45 per share being discussed, Street Insider says 09/21/22 DXC Technology working with advisers after takeover interest, Bloomberg says 09/21/22 DXC Technology working with advisers after takeover interest, Bloomberg says BKR Baker Hughes $30.54 / -0.13 (-0.42%) 11/04/22 Putin allows Russian company to buy Baker Hughes assets, Reuters reports 11/04/22 Putin allows Russian company to buy Baker Hughes assets, Bloomberg says WHD TEVA TEL SLB SCHW RIG RBLX PTEN PM OLED KPTI IBM HP HAL GEHC FTI DXC CVAC CTSH CHGG BKR WHD Cactus $51.81 / -0.96 (-1.82%) 01/10/23 Fly Intel: After-Hours Movers TEVA Teva $10.36 / -0.485 (-4.47%) 12/22/22 What You Missed On Wall Street On Thursday 12/22/22 What You Missed On Wall Street This Morning 11/19/22 Buy/Sell: Wall Street's top 10 stock calls this week 11/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations TEL TE Connectivity $121.17 / -2.06 (-1.67%) 12/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations SLB SLB $56.74 / -0.38 (-0.67%) 10/14/22 What You Missed On Wall Street On Friday 10/13/22 What You Missed On Wall Street On Thursday SCHW Charles Schwab $77.18 / -4.205 (-5.17%) 11/01/22 What You Missed On Wall Street On Tuesday 11/01/22 What You Missed On Wall Street This Morning RIG Transocean $5.87 / +0.15 (+2.62%) 10/06/22 What You Missed On Wall Street On Thursday 10/06/22 What You Missed On Wall Street This Morning 10/03/22 What You Missed On Wall Street On Monday 10/03/22 What You Missed On Wall Street This Morning RBLX Roblox $33.32 / -2.44 (-6.82%) 12/23/22 Buy/Sell: Wall Street's top 10 stock calls this week 12/21/22 What You Missed On Wall Street On Wednesday 12/21/22 What You Missed On Wall Street This Morning PTEN Patterson-UTI $16.10 / -0.01 (-0.06%) 12/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/27/22 What You Missed On Wall Street On Thursday 10/27/22 What You Missed On Wall Street This Morning 09/06/22 What You Missed On Wall Street On Tuesday PM Philip Morris $101.60 / +2.36 (+2.38%) 01/12/23 What You Missed On Wall Street On Thursday 01/12/23 What You Missed On Wall Street This Morning 11/15/22 What You Missed On Wall Street On Tuesday 11/15/22 What You Missed On Wall Street This Morning OLED Universal Display $127.44 / -0.06 (-0.05%) 11/03/22 Fly Intel: After-Hours Movers KPTI Karyopharm $3.26 / +0.19 (+6.20%) 12/12/22 What You Missed On Wall Street On Monday 12/12/22 What You Missed On Wall Street This Morning IBM IBM $141.12 / +0.73 (+0.52%) 01/18/23 What You Missed On Wall Street On Wednesday 01/18/23 What You Missed On Wall Street This Morning 01/18/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/20/22 What You Missed On Wall Street On Thursday HP Helmerich & Payne $47.17 / -0.355 (-0.75%) 10/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations HAL Halliburton $40.42 / -0.13 (-0.32%) 09/23/22 What You Missed On Wall Street On Friday 07/19/22 What You Missed On Wall Street On Tuesday 07/19/22 What You Missed On Wall Street This Morning GEHC GE HealthCare $62.75 / +0.74 (+1.19%) 01/04/23 What You Missed On Wall Street On Wednesday 01/04/23 What You Missed On Wall Street This Morning 12/10/22 Buy/Sell: Wall Street's top 10 stock calls this week FTI TechnipFMC $12.55 / +0.13 (+1.05%) 10/26/22 Fly Intel: After-Hours Movers DXC DXC Technology $28.35 / -0.615 (-2.12%) 10/04/22 What You Missed On Wall Street On Tuesday 09/21/22 What You Missed On Wall Street On Wednesday CVAC CureVac $9.87 / +0.385 (+4.06%) 01/19/23 Fly Intel: Pre-market Movers 01/09/23 What You Missed On Wall Street On Monday 01/09/23 What You Missed On Wall Street This Morning CTSH Cognizant $60.94 / -0.04 (-0.07%) 11/02/22 Fly Intel: After-Hours Movers 07/27/22 Fly Intel: After-Hours Movers CHGG Chegg $20.49 / +0.12 (+0.59%) 11/02/22 What You Missed On Wall Street On Wednesday 11/02/22 What You Missed On Wall Street This Morning BKR Baker Hughes $30.54 / -0.13 (-0.42%) 11/04/22 What You Missed On Wall Street On Friday 10/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/19/22 What You Missed On Wall Street On Wednesday 10/19/22 What You Missed On Wall Street This Morning 02/24/23 Annual Meeting of AAAAI 2023 01/20/23 SLB - SLB 01/23/23 Baker Hughes - BKR 01/24/23 Halliburton - HAL 01/25/23 TE Connectivity - TEL 01/25/23 IBM - IBM 01/30/23 GE HealthCare - GEHC 01/31/23 Helmerich & Payne - HP 02/02/23 Cognizant - CTSH 02/06/23 Chegg - CHGG 02/07/23 NOV Inc. - NOV 02/08/23 Teva - TEVA 02/09/23 Patterson-UTI - PTEN 02/15/23 Roblox - RBLX 02/22/23 ProPetro Holding - PUMP 02/09/23 GE HealthCare 02/28/23 Helmerich & Payne Inc 05/24/23 Universal Display TEVA SLB SCHW RIG RBLX PTEN PM NE IBM HP HAL GEHC FTI DXC CTSH BKR TEVA Teva $10.36 / -0.485 (-4.47%) 01/10/23 Unusually active option classes on open January 10th 01/04/23 Unusually active option classes on open January 4th 01/03/23 Teva call volume above normal and directionally bullish 12/22/22 Teva call volume above normal and directionally bullish SLB SLB $56.74 / -0.38 (-0.67%) 12/20/22 Schlumberger call volume above normal and directionally bullish 11/21/22 Schlumberger put volume heavy and directionally bearish 10/21/22 Early notable gainers among liquid option names on October 21st 10/21/22 Unusually active option classes on open October 21st SCHW Charles Schwab $77.18 / -4.205 (-5.17%) 01/18/23 Unusually active option classes on open January 18th 01/05/23 Charles Schwab call volume above normal and directionally bullish 09/23/22 Charles Schwab call volume above normal and directionally bullish RIG Transocean $5.87 / +0.15 (+2.62%) 11/02/22 Transocean options imply 7.9% move in share price post-earnings 09/15/22 Unusually active option classes on open September 15th 09/14/22 Unusually active option classes on open September 14th 08/01/22 Transocean options imply 8.9% move in share price post-earnings RBLX Roblox $33.32 / -2.44 (-6.82%) 12/27/22 Roblox call volume above normal and directionally bullish 10/18/22 Notable open interest changes for October 18th 10/17/22 Unusually active option classes on open October 17th 10/06/22 Roblox Corp put volume heavy and directionally bearish PTEN Patterson-UTI $16.10 / -0.01 (-0.06%) 10/26/22 Patterson-UTI options imply 10.8% move in share price post-earnings 08/15/22 Put seller in Patterson Energy opens 32-day position 22% below spot 08/15/22 Unusually active option classes on open August 15th PM Philip Morris $101.60 / +2.36 (+2.38%) 01/19/23 Early notable gainers among liquid option names on January 19th 10/31/22 Philip Morris put volume heavy and directionally bearish 09/23/22 Philip Morris put volume heavy and directionally bearish NE Noble Corp. $40.02 / +0.295 (+0.74%) 01/13/23 Largest borrow rate increases among liquid names IBM IBM $141.12 / +0.73 (+0.52%) 12/15/22 IBM put volume heavy and directionally bearish 10/20/22 Early notable gainers among liquid option names on October 20th 10/19/22 IBM options imply 5.0% move in share price post-earnings 09/13/22 IBM put volume heavy and directionally bearish HP Helmerich & Payne $47.17 / -0.355 (-0.75%) 11/16/22 Helmerich & Payne options imply 5.1% move in share price post-earnings HAL Halliburton $40.42 / -0.13 (-0.32%) 12/20/22 Early notable gainers among liquid option names on December 20th 12/16/22 Halliburton call volume above normal and directionally bullish 12/15/22 Halliburton put volume heavy and directionally bearish GEHC GE HealthCare $62.75 / +0.74 (+1.19%) 01/17/23 Largest borrow rate increases among liquid names 01/10/23 Four new option listings and two option delistings on January 10th FTI TechnipFMC $12.55 / +0.13 (+1.05%) 07/27/22 FMC Technologies options imply 8.3% move in share price post-earnings DXC DXC Technology $28.35 / -0.615 (-2.12%) 10/19/22 DXC Technology call volume above normal and directionally bullish 10/18/22 DXC Technology call volume above normal and directionally bullish 10/03/22 DXC Technology Co call volume above normal and directionally bullish 09/29/22 DXC Technology call volume above normal and directionally bullish CTSH Cognizant $60.94 / -0.04 (-0.07%) 01/12/23 Early notable gainers among liquid option names on January 12th 01/11/23 Largest borrow rate increases among liquid names BKR Baker Hughes $30.54 / -0.13 (-0.42%) 01/03/23 Baker Hughes call buyer realizes 12% same-day gains 11/07/22 Baker Hughes call volume above normal and directionally bullish 10/19/22 Early notable gainers among liquid option names on October 19th 09/13/22 Early notable gainers among liquid option names on September 13th
Initiation	Alpine Immune Sciences initiated with an Overweight at Morgan Stanley » 05:42 01/19/23 01/19 05:42 01/19/23 05:42 ALPN Alpine Immune Sciences $8.09 / -0.415 (-4.88%) Morgan Stanley analyst… Morgan Stanley analyst Michael Ulz initiated coverage of Alpine Immune Sciences with an Overweight rating and $17 price target. He believes ALPN-303, which he sees having potential across a range of inflammatory and autoimmune diseases, is "underappreciated" and thinks data in the second half of this year could provide early derisking in systemic lupus erythematosus, or SLE, as well as other indications, such as IgAN, Ulz tells investors. ShowHide Related Items >><< Company News Street Research Earnings Syndicate ALPN Alpine Immune Sciences $8.09 / -0.415 (-4.88%) 10/24/22 Alpine Immune Sciences terminates enrollment of davoceticept clinical studies ALPN Alpine Immune Sciences $8.09 / -0.415 (-4.88%) 11/21/22 SVB Securities Alpine Immune Sciences initiated with an Outperform at SVB Securities 10/24/22 Oppenheimer Alpine Immune price target lowered to $14 from $17 at Oppenheimer 10/24/22 H.C. Wainwright Alpine Immune Sciences price target lowered to $8 from $21 at H.C. Wainwright 03/07/22 Oppenheimer Alpine Immune Sciences price target lowered to $17 from $19 at Oppenheimer ALPN Alpine Immune Sciences $8.09 / -0.415 (-4.88%) 11/14/22 Alpine Immune Sciences reports Q3 EPS (42c), consensus (10c) 08/11/22 Alpine Immune Sciences reports Q2 EPS (60c), consensus (39c) 21 Sep
Initiation	Alpine Immune Sciences initiated with an Outperform at SVB Securities » 06:09 11/21/22 11/21 06:09 11/21/22 06:09 ALPN Alpine Immune Sciences $6.52 / +0.04 (+0.62%) SVB Securities analyst… SVB Securities analyst Thomas Smith initiated coverage of Alpine Immune Sciences with an Outperform rating and $15 price target. ShowHide Related Items >><< Company News Street Research Earnings Syndicate ALPN Alpine Immune Sciences $6.52 / +0.04 (+0.62%) 10/24/22 Alpine Immune Sciences terminates enrollment of davoceticept clinical studies 06/07/22 Alpine Immune Sciences appoints Sandler as CMO 05/26/22 Alpine Immune Sciences to present data on ALPN-303 and ALPN-202 candidates 05/24/22 FDA removes partial clinical hold on NEON-2 trial of ALPN-202 davoceticept combo ALPN Alpine Immune Sciences $6.52 / +0.04 (+0.62%) 10/24/22 Oppenheimer Alpine Immune price target lowered to $14 from $17 at Oppenheimer 10/24/22 H.C. Wainwright Alpine Immune Sciences price target lowered to $8 from $21 at H.C. Wainwright 03/07/22 Oppenheimer Alpine Immune Sciences price target lowered to $17 from $19 at Oppenheimer 03/07/22 H.C. Wainwright Alpine Immune clinical hold likely temporary, says H.C. Wainwright ALPN Alpine Immune Sciences $6.52 / +0.04 (+0.62%) 11/14/22 Alpine Immune Sciences reports Q3 EPS (42c), consensus (10c) 08/11/22 Alpine Immune Sciences reports Q2 EPS (60c), consensus (39c) 21 Sep
Earnings	Alpine Immune Sciences reports Q3 EPS (42c), consensus (10c) » 16:08 11/14/22 11/14 16:08 11/14/22 16:08 ALPN Alpine Immune Sciences $5.81 / +0.05 (+0.87%) Reports Q3 revenue… Reports Q3 revenue $8.37M, consensus $18.68M. "During our inaugural R&D Day and throughout subsequent scientific meetings this fall, we have shared promising nonclinical and clinical data that supports the best-in-class potential for our lead program ALPN-303 in multiple autoimmune and inflammatory indications. In particular, recent data from healthy volunteers presented at ASN's Kidney Week demonstrated dose-dependent reductions in Gd-IgA1, a key effector molecule and clinical biomarker of disease progress in IgAN, and the first clinical disease-related biomarker data with ALPN-303," said Mitchell H. Gold, MD, Executive Chairman and Chief Executive Officer of Alpine. "To further accelerate development of this promising program in multiple indications, we completed a successful $113 million follow-on offering with top-tier investors in October, extending our cash runway through the end of 2025. We now look forward to beginning a broad development plan for ALPN-303, including a phase 2 study in systemic lupus erythematosus (SLE). In addition, we are particularly excited to begin open-label basket studies in glomerulonephritis and autoimmune cytopenias as they should provide a rapid assessment in multiple diseases and may potentially enable multiple accelerated development paths." ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events ALPN Alpine Immune Sciences $5.81 / +0.05 (+0.87%) 10/24/22 Alpine Immune Sciences terminates enrollment of davoceticept clinical studies 06/07/22 Alpine Immune Sciences appoints Sandler as CMO 05/26/22 Alpine Immune Sciences to present data on ALPN-303 and ALPN-202 candidates 05/24/22 FDA removes partial clinical hold on NEON-2 trial of ALPN-202 davoceticept combo ALPN Alpine Immune Sciences $5.81 / +0.05 (+0.87%) 10/24/22 Oppenheimer Alpine Immune price target lowered to $14 from $17 at Oppenheimer 10/24/22 H.C. Wainwright Alpine Immune Sciences price target lowered to $8 from $21 at H.C. Wainwright 03/07/22 Oppenheimer Alpine Immune Sciences price target lowered to $17 from $19 at Oppenheimer 03/07/22 H.C. Wainwright Alpine Immune clinical hold likely temporary, says H.C. Wainwright ALPN Alpine Immune Sciences $5.81 / +0.05 (+0.87%) 08/11/22 Alpine Immune Sciences reports Q2 EPS (60c), consensus (39c) 21 Sep 11/14/22 Alpine Immune Sciences - ALPN
Recommendations	Alpine Immune price target lowered to $14 from $17 at Oppenheimer » 16:22 10/24/22 10/24 16:22 10/24/22 16:22 ALPN Alpine Immune Sciences $5.45 / -0.25 (-4.39%) Oppenheimer analyst Mark… Oppenheimer analyst Mark Breidenbach lowered the firm's price target on Alpine Immune Sciences to $14 from $17 and keeps an Outperform rating on the shares. The company announced a second Grade 5 cardiogenic shock incident in its NEON-2 study, triggering the discontinuation of patient enrollment in NEON-1 and NEON-2, Breidenbach tells investors in a research note. The analyst sees this news as the de facto end of Alpine's conditional CD28 agonist, davoceticept. He believes the recent $100M equity financing could extend Alpine's operational runway through 2025. ShowHide Related Items >><< Company News Street Research Earnings Syndicate ALPN Alpine Immune Sciences $5.45 / -0.25 (-4.39%) 10/24/22 Alpine Immune Sciences terminates enrollment of davoceticept clinical studies 06/07/22 Alpine Immune Sciences appoints Sandler as CMO 05/26/22 Alpine Immune Sciences to present data on ALPN-303 and ALPN-202 candidates 05/24/22 FDA removes partial clinical hold on NEON-2 trial of ALPN-202 davoceticept combo ALPN Alpine Immune Sciences $5.45 / -0.25 (-4.39%) 10/24/22 H.C. Wainwright Alpine Immune Sciences price target lowered to $8 from $21 at H.C. Wainwright 03/07/22 Oppenheimer Alpine Immune Sciences price target lowered to $17 from $19 at Oppenheimer 03/07/22 H.C. Wainwright Alpine Immune clinical hold likely temporary, says H.C. Wainwright ALPN Alpine Immune Sciences $5.45 / -0.25 (-4.39%) 08/11/22 Alpine Immune Sciences reports Q2 EPS (60c), consensus (39c) 05/12/22 Alpine Immune Sciences reports Q1 EPS (25c), consensus (19c) 21 Sep

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial